Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119831
Chunk: 242

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 242
---
 million

153

lives, with the remaining 25 million to be considered in the future. Currently, ZTlido is covered for over 200 million lives in the United States and coverage continues to improve. As of January 2023, we have secured coverage for ZTlido on CVS Caremark/Aetna Commercial, Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and most Medicare plans), United Healthcare Commercial, Optum Rx Select Commercial, Anthem BCBS, BCBS Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Elixir Commercial and Medicaid in California, Florida, Idaho, and North Dakota. We continue to negotiate coverage with large payors and pharmacy benefit managers in all books of business. ZTlido Formulary Coverage — Over 90% of Lives Covered or In Negotiation We utilize an outside vendor to administer a patient assistance program directed at patients with commercial insurance or those paying out-of-pocket.With the co-payassistance program, qualifying patients do not have to pay any co-paymentfor their ZTlido prescription. We utilize an external vendor and train the sales force to work proactively with clinician office managers in completing required forms for prior authorization for ZTlido. Clinical Development Overview ZTlido Clinical Trial Highlights We have evaluated ZTlido in over 600 subjects in clinical trials to support marketing approval and promotional campaigns for the relief of neuropathic pain associated with PHN in the United States. Our studies sought to investigate the bioequivalence of ZTlido compared to Lidoderm, adhesion performance and the dermal safety and tolerability of ZTlido under a range of application times and settings. Based on these studies, we concluded that ZTlido:

| • |     | demonstrated bioequivalence to Lidoderm in study 
 SCI-LIDO-PK-002A;                                |

| • |     | showed greater than or equal to 90% adhesion in over 90% of the subjects at the end of the 12-hour administration period in study SCI-LIDO-ADH-001; |

| • |     | showed superior adhesion to Lidoderm and Mylan’s generic lidocaine patch in studies SCI-LIDO-AHD-002 and 
 SCI-LIDO-ADH-003;                                                                                        |

| • |     | was not meaningfully impacted by heat or exercise in study SCI-LIDO-HEX-001; |

154

| •